251 related articles for article (PubMed ID: 23823316)
1. Myeloproliferative neoplasms and thrombosis.
Barbui T; Finazzi G; Falanga A
Blood; 2013 Sep; 122(13):2176-84. PubMed ID: 23823316
[TBL] [Abstract][Full Text] [Related]
2. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study.
Ghirardi A; Carobbio A; Guglielmelli P; Rambaldi A; De Stefano V; Vannucchi AM; Tefferi A; Barbui T
Blood Cancer J; 2024 Apr; 14(1):68. PubMed ID: 38649342
[No Abstract] [Full Text] [Related]
3. Understanding and modifying thrombotic risk in patients with myeloproliferative neoplasms.
Krecak I; Sabljic A; Lucijanic M
J Cardiol; 2023 Jun; 81(6):586. PubMed ID: 36592886
[No Abstract] [Full Text] [Related]
4. Pulmonary Hypertension in Myeloproliferative Neoplasms: New Insights and Unexplored Horizons.
Leiva O; Garcia BD; Hobbs G
Am J Respir Crit Care Med; 2023 Sep; 208(5):518-521. PubMed ID: 37429036
[No Abstract] [Full Text] [Related]
5. Thrombosis in myeloproliferative neoplasms.
Falanga A; Marchetti M
Semin Thromb Hemost; 2014 Apr; 40(3):348-58. PubMed ID: 24610470
[TBL] [Abstract][Full Text] [Related]
6. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
7. Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncology (ÖGHO) and Society of Thrombosis and Haemostasis Research (GTH e.V.).
Kreher S; Ochsenreither S; Trappe RU; Pabinger I; Bergmann F; Petrides PE; Koschmieder S; Matzdorff A; Tiede A; Griesshammer M; Riess H; ; ;
Ann Hematol; 2014 Dec; 93(12):1953-63. PubMed ID: 25307456
[TBL] [Abstract][Full Text] [Related]
8. Myeloproliferative Neoplasms: A Contemporary Review.
Tefferi A; Pardanani A
JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms.
Rumi E; Cazzola M
Blood; 2017 Feb; 129(6):680-692. PubMed ID: 28028026
[TBL] [Abstract][Full Text] [Related]
10. Novel insights into the biology and treatment of chronic myeloproliferative neoplasms.
Mughal TI; Barbui T; Abdel-Wahab O; Kralovics R; Jamieson C; Kvasnicka HM; Mullaly A; Rampal R; Mesa R; Kiladjian JJ; Deininger M; Prchal J; Hehlmann R; Saglio G; Van Etten RA
Leuk Lymphoma; 2015 Jul; 56(7):1938-48. PubMed ID: 25330439
[TBL] [Abstract][Full Text] [Related]
11. Splanchnic vein thrombosis in myeloproliferative neoplasms: pathophysiology and molecular mechanisms of disease.
How J; Zhou A; Oh ST
Ther Adv Hematol; 2017 Mar; 8(3):107-118. PubMed ID: 28246554
[TBL] [Abstract][Full Text] [Related]
12. Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry.
Kaifie A; Kirschner M; Wolf D; Maintz C; Hänel M; Gattermann N; Gökkurt E; Platzbecker U; Hollburg W; Göthert JR; Parmentier S; Lang F; Hansen R; Isfort S; Schmitt K; Jost E; Serve H; Ehninger G; Berdel WE; Brümmendorf TH; Koschmieder S;
J Hematol Oncol; 2016 Mar; 9():18. PubMed ID: 26944254
[TBL] [Abstract][Full Text] [Related]
13. Splanchnic vein thrombosis and myeloproliferative neoplasms: molecular-driven diagnosis and long-term treatment.
De Stefano V; Qi X; Betti S; Rossi E
Thromb Haemost; 2016 Jan; 115(2):240-9. PubMed ID: 26333846
[TBL] [Abstract][Full Text] [Related]
14. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Vannucchi AM; Barbui T; Cervantes F; Harrison C; Kiladjian JJ; Kröger N; Thiele J; Buske C;
Ann Oncol; 2015 Sep; 26 Suppl 5():v85-99. PubMed ID: 26242182
[No Abstract] [Full Text] [Related]
15. Splanchnic vein thrombosis in myeloproliferative neoplasms.
Sekhar M; McVinnie K; Burroughs AK
Br J Haematol; 2013 Sep; 162(6):730-47. PubMed ID: 23855810
[TBL] [Abstract][Full Text] [Related]
16. Myeloproliferative Neoplasms.
Spivak JL
N Engl J Med; 2017 Jun; 376(22):2168-2181. PubMed ID: 28564565
[No Abstract] [Full Text] [Related]
17. How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Titmarsh GJ; Duncombe AS; McMullin MF; O'Rorke M; Mesa R; De Vocht F; Horan S; Fritschi L; Clarke M; Anderson LA
Am J Hematol; 2014 Jun; 89(6):581-7. PubMed ID: 24971434
[TBL] [Abstract][Full Text] [Related]
18. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Stein BL; Moliterno AR; Tiu RV
Ann Hematol; 2014 Dec; 93(12):1965-76. PubMed ID: 25270596
[TBL] [Abstract][Full Text] [Related]
19. JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.
Rumi E; Pietra D; Ferretti V; Klampfl T; Harutyunyan AS; Milosevic JD; Them NC; Berg T; Elena C; Casetti IC; Milanesi C; Sant'antonio E; Bellini M; Fugazza E; Renna MC; Boveri E; Astori C; Pascutto C; Kralovics R; Cazzola M;
Blood; 2014 Mar; 123(10):1544-51. PubMed ID: 24366362
[TBL] [Abstract][Full Text] [Related]
20. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia.
Ann Intern Med; 1995 Nov; 123(9):656-64. PubMed ID: 7574220
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
